CClinicalTrials.gg
RecruitingNCT04307992Updated Jun 7, 2024

AneuFix - Prophylactic Sac Filling

An interventional study of Prophylactic sac filling with AneuFix in Abdominal Aortic Aneurysm and Endoleak, sponsored by TripleMed B.V.. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-07.

Sponsored by TripleMed B.V. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is set up to assess the feasibility and safety of the clinical procedure using AneuFix in a prophylactic setting at the time of EVAR endograft implantation.

Read the detailed description

The investigational device is called ANEUFIX, which is a product treating the endoleak by blockage of backflowing blood vessels, i.e. by filling the endoleak void and nidus of feeding artery and exit of existing draining arteries.

ANEUFIX is a polymer that cures rapidly (2-4 min at 37°C) after injection into the AAA-sac close to the nidus.

02

Conditions studied

  • Abdominal Aortic Aneurysm
  • Endoleak
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Asymptomatic, infrarenal AAA that requires surgery with a high-risk profile of developing endoleak type II in line with the recommendations of Guntner et al:

    • Open IMA AND
    • 1 patent lumbar AND a cross-sectional area at the location of the IMA (CSAIMA) >17,5cm2 OR
    • 2 patent lumbars AND a CSAIMA >15cm2 OR
    • 3 patent lumbars AND a CSAIMA >12,5 cm2 OR
    • 4 patent lumbars AND a CSAIMA >10 cm2 OR
    • 5 patent lumbars AND a CSAIMA >7,5 cm2
  • Infrarenal neck according to the IFU of the EVAR device
  • Other aortic-iliac anatomical configuration suitable for EVAR according to the criteria of the EVAR device to be used
  • Patient having a life expectation of at least 2 years
  • Being older than 18 years
  • Willing and able to comply with the requirements of this clinical study

Exclusion criteria

Exclusion Criteria:

  • Patient not able or willing to give written Informed Consent
  • Patient undergoing emergency procedures
  • Patient undergoing EVAR for ruptured or symptomatic AAA,
  • Patient with a suprarenal AAA
  • Patient with an inflammatory AAA (more than minimal wall thickening)
  • Patient with an infrarenal neck unsuitable for endovascular fixation (including so called "hostile necks") or aortic-iliac anatomic configuration otherwise unsuitable for EVAR according to criteria of the device to be used
  • Patient in which a bilateral retroperitoneal incision is required for EVAR
  • Patient in which a sacrifice of both hypogastric arteries is required
  • Patient with anatomical variations, i.e. horseshoe-kidney, arteries requiring reimplantation
  • Patient in which the administration of contrast agent is not possible: proved, severe systemic reaction to contrast agent
  • Patient with active infection present
  • Patients scheduled for or having received an organ transplant
  • Patient with limited life expectation due to other illness (\<1 year)
  • Patient with non-iatrogenic bleeding diathesis
  • Patient with connective tissue disease
  • Women of child-bearing potential
  • Patients with evidence at completion angiogram during EVAR of a type Ia or type III endoleak persistent after balloon inflation
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    Intervention

    Device: ANEUFIX

    Device: Prophylactic sac filling with AneuFix

Interventions

  • DeviceProphylactic sac filling with AneuFix

    ANEUFIX is administered by injection into the AAA via transferal access at the time of EVAR placement using imaging techniques to guide the place of injection.

05

What researchers measure

Primary outcomes

  1. Technical Success

    Technical Success as demonstrated by the feasibility to fill the AAA sac after EVAR during the same procedure, and by the rate of (all) endoleaks after EVAR followed by the AneuFix procedure

    Time frame: 24 hours

  2. Clinical Success rate

    Clinical Success as demonstrated by the occurrence of type II endoleaks at 6 months after EVAR, and aneurysmal sac growth at 6 months after EVAR

    Time frame: 6 months

  3. Clinical Success rate

    Clinical Success as demonstrated by the occurrence of type II endoleaks at 12 months after EVAR, and aneurysmal sac growth at 12 months after EVAR

    Time frame: 12 months

Secondary outcomes

  1. Intraoperative occurrence of complications

    Adverse events occurring during the surgical intervention are registered.

    Time frame: 24 hours

  2. Peri-operative complications

    Rate of peri-operative complications

    Time frame: 30 days

  3. Prevention of (any type of) endoleak

    Occurrence of (any type of) endoleak

    Time frame: 1, 6 and 12 months

  4. adverse events

    Occurrence of adverse events and adverse device effects

    Time frame: 1, 6 and 12 months

  5. Re-interventions

    Rate of secondary endovascular or surgical re-interventions

    Time frame: 1, 6 and 12 months

  6. Aneurysm rupture

    Rate of aneurysm rupture

    Time frame: 6 and 12 months

  7. Proportion of patients surviving 24 months after treatment

    Survival throughout the study up until 24 months

    Time frame: 24 months

06

Study locations

1 of 1 sites recruiting
07

Registry details

Key details

Study ID
NCT04307992
Lead sponsor
TripleMed B.V.
Responsible party
Sponsor
First posted
Mar 13, 2020
Start date
Feb 15, 2022
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 7, 2024

Study contacts

Florie Daniels
Contact
f.daniels@triple-med.com
+31 6 38 19 92 91
Tjeerd Homsma
Contact
t.homsma@triple-med.com
+31 6 29 07 80 03
Arjan WJ Hoksbergen, Dr
principal investigator · VUmc Heelkunde, Amsterdam

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion